Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q4 2024

Q4 2024 biggest moves
  • NUVLNUVL

    NUVALENT

    Cut 10%

    now 27% of portfolio

  • KURAKURA

    Kura Oncology

    Sold out

    was 1.6% of portfolio

  • NAMSNAMS

    NewAmsterdam Pharma

    4.8× the shares

    now 2.1% of portfolio

  • DVAXDVAX

    DYNAVAX TECHNOLOGIES

    241× the shares

    now 1.3% of portfolio

432 changes in all

Top Holdings106 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

18M$1.4B26.7%——
14 qtrssince 2021-Q3
Decreased
0
VTRS

Viatris Inc.

24M$298.8M5.7%$11.16+3.72%
17 qtrssince 2020-Q4
Increased
60
174.4M$168.2M3.2%——
4 qtrssince 2024-Q1
Unchanged
0
CNC

Centene Corporation

2.7M$161.9M3.1%$67.92-10.81%
21 qtrssince 2019-Q4
Increased
56
OSCR

Oscar Health, Inc.

11.8M$159.1M3.0%$11.50+16.84%
5 qtrssince 2023-Q4
Increased
77
RVMD

Revolution Medicines, Inc.

3.3M$142.5M2.7%$27.88+56.89%
20 qtrssince 2020-Q1
Increased
58
MRUS
MRUSDelisted

MERUS N V

3M$125M2.4%——
13 qtrssince 2021-Q4
Decreased
0
??
ACCOLADE INCDelisted
Bond
132.6M$124.5M2.4%——
11 qtrssince 2022-Q2
Unchanged
0
WAY

Waystar Holding Corp.

3.3M$120.9M2.3%——
3 qtrssince 2024-Q2
Decreased
0
NBIX

Neurocrine Biosciences, Inc.

862,000$117.7M2.2%$105.09+29.89%
16 qtrssince 2021-Q1
Decreased
0
110M$117.3M2.2%——
2 qtrssince 2024-Q3
Increased
57
SPRY

ARS Pharmaceuticals, Inc.

10.5M$110.9M2.1%$8.53+23.68%
9 qtrssince 2022-Q4
Decreased
0
NAMS

NewAmsterdam Pharma Company N.V.

4.3M$110.9M2.1%$25.01+2.76%
4 qtrssince 2024-Q1
Increased
83
INDV
INDVDelisted

INDIVIOR PLC

8.9M$110.4M2.1%$8.45+14.10%
2 qtrssince 2024-Q3
Increased
78
70M$106.6M2.0%——
3 qtrssince 2024-Q2
Unchanged
0
AHCO

AdaptHealth Corp.

9.7M$92.5M1.8%$18.05-47.25%
21 qtrssince 2019-Q4
Unchanged
0
ALHC

Alignment Healthcare, Inc.

7.3M$82.2M1.6%$6.20+81.56%
7 qtrssince 2023-Q2
Decreased
0
LRMR

Larimar Therapeutics, Inc.

21.2M$82.2M1.6%$6.64-41.71%
19 qtrssince 2020-Q2
Unchanged
0
BKD

Brookdale Senior Living Inc.

15.6M$78.5M1.5%$4.41+14.05%
21 qtrssince 2019-Q4
Unchanged
0
IDYA

IDEAYA Biosciences, Inc.

2.7M$70.3M1.3%$22.01+16.75%
10 qtrssince 2022-Q3
Increased
49
$5.3B
AUM
106
Positions
Q4 2024
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2023-Q3$4,538,793,245-3.10411836992%
2023-Q4$5,415,638,75919.3189129063%
2024-Q1$5,748,069,8946.13835504533%
2024-Q2$6,010,510,6294.56571927342%
2024-Q3$6,692,805,83111.3517011135%
2024-Q4$5,280,006,191-21.1092279632%
Activity profile
$ moved · Q4'24
New8%Increased20%Decreased46%Exited25%
Composition
Equity vs derivatives
Equity>99%Puts<1%Calls0%
Holding period
Avg 2.2 years
<1Q11%1-4Q17%1-2Y12%2Y+59%

Deerfield Management Company, L.P. manages $5.3B across 106 positions as of Q4 2024. Top holdings: NUVL (26.7%), VTRS (5.7%), INTEGRA LIFESCIENCES HLDGS C (3.2%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
NUVL26.67%
VTRS5.66%
INTEGRA LIFE3.19%
CNC3.07%
OSCR3.01%
RVMD2.70%
MRUS2.37%
ACCOLADE INC2.36%
WAY2.29%
NBIX2.23%
Other2.22%

Portfolio allocation by GICS sector

Sectors9
Healthcare99.06%
Unknown0.92%
Consumer Defensive0.01%
Industrials0.00%
Technology0.00%
Energy0.00%
Financial Services0.00%
Basic Materials0.00%
Real Estate0.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used